{"id":2206,"date":"2017-12-29T20:23:16","date_gmt":"2017-12-29T20:23:16","guid":{"rendered":"https:\/\/www.medicalmarijuanainc.com\/?p=33734"},"modified":"2017-12-29T20:23:16","modified_gmt":"2017-12-29T20:23:16","slug":"medical-marijuana-inc-2017-year-review","status":"publish","type":"post","link":"https:\/\/medicalmarijuanainc.com\/2017\/12\/29\/medical-marijuana-inc-2017-year-review\/","title":{"rendered":"Medical Marijuana, Inc. 2017 Year in Review"},"content":{"rendered":"
[vc_row][vc_column][vc_column_text]Along with our portfolio of companies, Medical Marijuana, Inc. looks to continue to build on the success this past year.<\/span><\/i><\/p>\n Medical Marijuana, Inc. and our family of companies had an impressive year in 2017, breaking company records, innovating exciting new products, and reaching more customers than ever before. We hosted and sponsored educational events for customers, patients, and doctors around the world, helping to spread awareness for CBD and dispel myths surrounding its use. We helped positively shape the conversation regarding cannabis on an international stage and and affected real change in cannabis policy, opening cannabinoids to those who were once blocked from access. <\/span><\/p>\n Medical Marijuana, Inc. and its portfolio of companies saw unprecedented sales growth in 2017, growing their share of the CBD oil market, a market expected to reach <\/span>$1 billion by 2020<\/span><\/a>. <\/span><\/p>\n In Q2 of 2017, we experienced a <\/span>269% revenue increase<\/span><\/a> from the same quarter in 2016. We saw similar growth in Q3 when Medical Marijuana Inc. announced a <\/span>255% year-over-year increase<\/span><\/a> in gross revenue.<\/span><\/p>\n [\/vc_column_text][vc_video link=”https:\/\/www.youtube.com\/watch?time_continue=1&v=dcG17Iq2Tuo”][\/vc_column][\/vc_row]<\/p>\n Medical Marijuana, Inc. set <\/span>company record for sales revenue<\/span><\/a> in November, a feat it also achieved in <\/span>August<\/span><\/a> and <\/span>July<\/span><\/a>. Portfolio companies <\/span>Kannaway<\/span><\/a> and <\/span>HempMeds\u00ae Mexico<\/span><\/a> both had their highest sales revenue month\u2019s ever in November. <\/span><\/p>\n To keep up with this growth, Medical Marijuana, Inc. more than <\/span>tripled the size of its fulfillment center<\/span><\/a> and doubled the size of its corporate offices, both located in San Diego. This added space and ability to increase staff size ensures Medical Marijuana, Inc. can keep pace with its rapidly growing share of the hemp market. <\/span><\/p>\n This year, our portfolio of companies made several key hires and promotions for high-profile positions to support its rapid growth. <\/span><\/p>\n These top hires include <\/span><\/p>\n Medical Marijuana, Inc. continued to work toward its goal of access to cannabinoids for everyone by focusing effort on our international expansion. <\/span><\/p>\n Subsidiary <\/span>HempMeds\u00ae Mexico<\/span><\/a> opened its <\/span>first in-country office<\/span><\/a> in Monterrey, allowing the company to better serve patients and doctors in the country looking to prescribe or use CBD oil as a treatment option.<\/span><\/p>\n Kannaway <\/span>launched full business operations in Europe<\/span><\/a> less than a year after announcing its <\/span>intention to enter the European Union market<\/span><\/a>. The company has set up a European distribution center in Poland and has begun shipping select Kannaway products directly from its EU location. <\/span><\/p>\n Medical Marijuana, Inc. was also active in positively affecting cannabis reform around the world this year, helping to ensure cannabinoid access for those who need it. <\/span><\/p>\n Earlier this year, Medical Marijuana, Inc. <\/span>applauded the legalization of medical marijuana in Mexico<\/span><\/a>. Medical Marijuana, Inc. and our subsidiary HempMeds\u00ae Mexico were integral in helping the grassroots movement for access to legal cannabinoids like CBD, and President of HempMeds\u00ae Mexico Raul Elizalde <\/span>spoke on stage with Mexican President Pe\u00f1a Nieto<\/span><\/a> when he first announced his intention to reform Mexico\u2019s cannabis policy. <\/span><\/p>\n Additionally, this year, Medical Marijuana, Inc. products were <\/span>subsidized by the government of Mexico<\/span><\/a> for the first time. This important step for access helps normalize cannabis-based prescriptions in Mexico and around the world. <\/span><\/p>\n Finally, President of HempMeds\u00ae Mexico Raul Elizalde <\/span>spoke at the World Health Organization<\/span><\/a> (WHO) to help influence the organization\u2019s policy on CBD. After review and testimony from speakers like Raul, the <\/span>WHO decided that CBD should not be scheduled<\/span><\/a>. <\/span><\/p>\n Medical Marijuana, Inc. was also active this year in cannabinoid-based research and medical studies aimed at creating novel new drugs for a range of medical conditions. <\/span><\/p>\n Medical Marijuana, Inc. investment <\/span>AXIM\u00ae Biotechnologies<\/span><\/a> has started to develop a product that is <\/span>bioequivalent to Marinol<\/span><\/a>. This will allow the company to take advantage of an existing prescription medication market with its improved chewing gum consumption method. <\/span><\/p>\n AXIM\u00ae Biotech has taken steps, including clinical trials, for the approval of drugs aimed at conditions like<\/span><\/p>\n In addition to clinical trials conducted by Medical Marijuana, Inc. investments like AXIM\u00ae Biotech, our products were also featured in research by outside entities for a pair of medical conditions. The results of these studies help to validate the use of cannabinoid-based products like those from Medical Marijuana, Inc.<\/span><\/p>\n Medical Marijuana, Inc. will continue to pursue avenues for the development and approval of cannabinoid-based medications in the coming years as the medical benefits of cannabis become better understood.<\/span><\/p>\n Medical Marijuana, Inc. and our subsidies participated in, sponsored, or hosted panel and informative discussions at nearly two dozen cannabis, health and wellbeing, and business and investment events in 2017. Our participation in these events allowed the Medical Marijuana, Inc. family of companies to promote the benefits of CBD and our CBD oil products to audiences across the U.S. and around the world. The events attended by Medical Marijuana, Inc. companies include<\/span><\/p>\n Additionally, some of our portfolio companies hosted our own events in the U.S. and internationally, giving them the opportunity to reach out face-to-face with our supporting community. <\/span><\/p>\n Kannaway held events nearly every month in 2017 to help build excitement for their line of hemp products and the opportunities presented by the Kannaway system. Kannaway regional Red Carpet events and twice-yearly national conventions feature top Kannaway executives, top-earning brand ambassadors, and special guest and give attendees the chance to educate themselves, build the skills necessary to excel, and network with fellow brand ambassadors. <\/span><\/p>\n Kannaway\u2019s events this year included<\/span><\/p>\n Kannaway Europe also held a <\/span>series of events across the European Union<\/span><\/a> to generate excitement surrounding Kannaway\u2019s launch in the region. These events were capped by Europe\u2019s first regional event in <\/span>Prague<\/span><\/a>. As with their U.S. market, Kannaway will regularly hold these regional events around Europe to help promote their unique hemp opportunities.<\/span><\/p>\nRevenue Growth<\/span><\/h2>\n
\n
International Expansion<\/span><\/h2>\n
<\/p>\n
Affected International Cannabinoid Policy<\/span><\/h2>\n
<\/p>\n
Clinical Studies and Research<\/span><\/h2>\n
\n
\n
<\/p>\n
Events<\/span><\/h2>\n
\n
<\/p>\n
\n
<\/p>\n